Liver-Targeted siRNA Lipid Nanoparticles Treat Hepatic Cirrhosis by Dual Antifibrotic and Anti-inflammatory Activities.
Zhang J, Shen H, Xu J, Liu L, Tan J, Li M, Xu N, Luo S, Wang J, Yang F, Tang J, Li Q, Wang Y, Yu L, Yan Z.
Zhang J, et al. Among authors: xu n, xu j.
ACS Nano. 2020 May 26;14(5):6305-6322. doi: 10.1021/acsnano.0c02633. Epub 2020 May 11.
ACS Nano. 2020.
PMID: 32378877